Abstract
Diltiazem, a calcium channel blocker, is known to suppress platelet function in vitro. However, its in vivo effects on platelets have been controversial. The effect of diltiazem on both human and calf platelets was studied using impedance whole-blood aggregometry. In vitro, platelet aggregation induced by ADP (5 microM) or collagen (1 micrograms/ml) was significantly suppressed by 0.1 to 1.0 mM (45 to 450 micrograms/ml) of diltiazem in both species. In calves weighting 70 to 90 kg, platelet aggregability did not change after the oral administration of 180 mg diltiazem. In this condition, diltiazem was not detected in plasma samples. Intravenous injection of 0.5 mg/kg diltiazem also did not significantly alter the aggregability, although the PR interval on the ECG elongated (40 msec, p < .05), mean arterial pressure dropped (14 mmHg, p < .05), and diltiazem was readily detected in plasma (199 ng/ml, 0.4 microM). In conclusion, platelet aggregability is not altered by a clinical dosage of diltiazem that is sufficient to induce hemodynamic changes with therapeutic plasma concentrations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of investigative surgery : the official journal of the Academy of Surgical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
